People: Novartis AG (NVS)

Summary

Name	Age	Since	Current Position
Daniel Vasella	60	2010	Chairman of the Board of Directors
Joseph Jimenez	53	2010	Chief Executive Officer, Member of the Executive Committee
Ulrich Lehner	67	2006	Vice Chairman of the Board of Directors, Non-Executive Director
Jon Symonds	54	2010	Chief Financial Officer, Member of the Executive Committee
Felix Ehrat	56	2012	Group General Counsel, Member of the Executive Committee
Juergen Brokatzky-Geiger	61	2005	Head Human Resources and Member of the Executive Committee
Kevin Buehler	55	2011	Member of the Executive Committee, Division Head, Alcon
David Epstein	51	2010	Member of the Executive Committee, Division Head, Pharmaceuticals
Mark Fishman	61	2002	Member of the Executive Committee and President of Novartis Institute for BioMedical Research (NIBR)
Jeff George	39	2010	Member of the Executive Committee and Division Head, Sandoz
George Gunn	62	2011	Member of the Executive Committee, Division Head, Novartis Animal Health of Head, Corporate Responsibility
Andrin Oswald	41	2008	Member of the Executive Committee, Division Head, Vaccines and Diagnostics
Dimitri Azar	54	2012	Member of the Board of Directors
William Brody	69	2009	Member of the Board of Directors
Srikant Datar	60	2003	Member of the Board of Directors
Ann Fudge	62	2008	Member of the Board of Directors
Pierre Landolt	66	1996	Member of the Board of Directors
Enrico Vanni	62	2011	Member of the Board of Directors
Andreas von Planta	57	2006	Member of the Board of Directors
Wendelin Wiedeking	61	2003	Member of the Board of Directors
Mun Tak Yang	61	2008	Member of the Board of Directors
Rolf Zinkernagel	69	1999	Member of the Board of Directors

» Insider Trading

Biographies

Name	Description
Daniel Vasella	Dr. Daniel L. Vasella, M.D., has served as Chairman of the Board of Directors of Novartis AG since February 1, 2010. In addition, he is Chairman of the Chairman's Committee at the Company. He resigned from his positions as Chief Executive Officer (CEO) of the Company on February 1, 2010. He had served as CEO and Executive Member of the Board of Directors of Novartis AG since the merger that created Novartis AG in 1996. He was appointed Company's Chairman of the Board of Directors in 1999. Befor the Novartis AG merger, Dr. Vasella was CEO of Sandoz Pharma Ltd. and Member of the Sandoz Group Executive Committee. From 1988 to 1992, he was with Sandoz Pharmaceuticals Corporation in the United States, prior to which he held a number of medical positions in Switzerland. Dr. Vasella is Member of the Board of Directors of PepsiCo, Inc. He is also Member of the International Board of Governors of the Peres Center for Peace in Israel, the International Business Leaders Advisory Council for the Mayor of Shanghai, the Global Health Program Advisory Panel of the Bill & Melinda Gates Foundation, and is a foreign Honorary Member of the American Academy of Arts and Sciences. He is also Member of the Board of Trustees of the Carnegie Endowment for International Peace. In addition, Dr. Vasella serves as Member of several industry associations and educational institutions. Dr. Vasella graduated with a Medical Doctor (M.D.) title from Universitaet Bern in 1979. Dr. Vasella has been honored with several awards, including the Harvard Business School's Alumni Achievement Award and Appeal of Conscience Award, the AJ Congress Humanitarian Award, the Ordem Nacional do Cruzeiro do Sul (Brazil), and holds the rank of Chevalier in the Ordre national de la Legion d'honneur (France). He was also awarded an honorary doctorate by the University of Basel.
Joseph Jimenez	Mr. Joseph (Joe) Jimenez has been Chief Executive Officer and Member of the Executive Committee of Novartis AG since February 1, 2010. Prior to that, he served as CEO - Pharmaceuticals Division as of October 2007. In the Company he is responsible for heading the Company's diversified healthcare portfolio of innovative pharmaceuticals, generics, vaccines and diagnostics and consumer health products. Previously, Mr. Jimenez served as Division Head, Novartis Pharmaceuticals. Mr. Jimenez joined Novartis in April 2007 as Division Head, Novartis Consumer Health. Previously, he served as President and Chief Executive Officer (CEO) of the North America business for the H.J. Heinz Company and as President and CEO of Heinz in Europe from 2002 to 2006. Prior to joining Novartis, he was a Non-Executive Director of Astra-Zeneca plc, United Kingdom, from 2002 to 2007. He was also an advisor for the private equity organization Blackstone Group in the United States. Mr. Jimenez is Member of the Board of Directors of Colgate-Palmolive. He graduated with a bachelors degree from Stanford University in 1982 and with a Master of Business Administration (MBA) degree from the University of California, Berkeley, in 1984.
Ulrich Lehner	Prof. Dr. Ulrich Lehner, Ph.D., has been Vice Chairman of the Board of Directors and Non-Executive Director of Novartis AG since 2006. He serves as Chairman of the Corporate Governance and Nomination Committee of the Company, as well as Member of the Audit and Compliance Committee, the Risk Committee, the Chairman’s Committee, and the Compensation Committee. He has acted as Non-Executive Director and Member of the Board of Directors of the Company since 2002. He has also co-woorked with the Audit Committee. From 1975 to 1981, he was an auditor with KPMG Deutsche Treuhand-Gesellschaft AG in Duesseldorf. In 1981, he joined Henkel KGaA. After heading the Controlling Department of Fried. Krupp GmbH in Germany from 1983 to 1986, Prof. Lehner returned to Henkel as Finance Director. From 1991 to 1994, he headed Henkel Asia-Pacific Ltd in Hong Kong, and from 1995 to 2000, served as Executive Vice President, Finance/Logistics, of Henkel KGaA. From 2000 to 2008, Prof. Lehner served as Chairman of the Management Board of Henkel KGaA. Prof. Lehner is Member of the Shareholders’ Committee of Henkel AG & Co. KGaA, Chairman of the Supervisory Board of Deutsche Telekom AG, and serves as Member of the Supervisory Boards of E.ON AG, ThyssenKrupp AG, Porsche Automobil Holding SE and Henkel Management AG, all in Germany. He is also Member of the Shareholders’ Committees of Dr. August Oetker KG and Krombacher Brauerei, both in Germany. Prof. Lehner graduated in business administration and mechanical engineering from Technische Universitaet Darmstadt (the Darmstadt University of Technology), Germany, in 1975.
Jon Symonds	Mr. Jonathan (Jon) R. Symonds has been Chief Financial Officer and Member of the Executive Committee of Novartis AG since February 1, 2010. Prior to that, he served as Deputy Chief Financial Officer at Novartis AG since September 1, 2009. He spent eight years as Chief Financial Officer at AstraZeneca, where his position encompassed Finance, Mergers and Acquisitions (M&A), Strategy, Information Technology (IT), Purchasing, Business Development and Licensing. Before that, he was Finance Director at Zeneca and previously was Partner at KPMG. From 2004 to 2007, Mr. Symonds was Director of Diageo Plc and Chairman of the Audit Committee. Other previous roles include director and Audit Committee chairman of Qinetiq Plc, chairman of the 100 Group of Finance Directors, joint chairman of the Business Tax Forum, board member of the Accounting Standards Board and founder of the Oxford University Centre for Business Taxation Research, all in the United Kingdom. Mr. Symonds graduated with a first class degree in business finance from the University of Hertfordshire, United Kingdom, in 1980 and became a Fellow of Chartered Accountants in 1982. He is a Commander of the British Empire (CBE).
Felix Ehrat	Dr. Felix R. Ehrat, Ph.D., has been Group General Counsel and Member of the Executive Committee of Novartis AG since January 1, 2012. He joined the Company in October 2011 as General Counsel and a permanent attendee of the Executive Committee. Dr. Ehrat is a practitioner of corporate, banking, and mergers and acquisitions law, as well a in corporate governance and arbitration. He started his career as an associate with Baer & Karrer Ltd. in Zurich in 1987, became Partner in 1992, and advanced to Senior Partner (2003 to 2011) and Executive Chairman of the Board (2007 to 2011) of the firm. Dr. Ehrat is Chairman of Globalance Bank AG in Switzerland, and Member of the Board of Liechtensteinische Landesbank AG in Liechtenstein. Previously, Dr. Ehrat was Chairman of Banca del Gottardo, and a Board Member of Julius Baer Holding AG, Austriamicrosystems AG, Charles Voegele Holding AG, and Carlo Gavazzi Holding AG. Mr. Ehrat was admitted to the Zurich bar in 1985 and received his doctorate of law from Universitaet Zuerich (the University of Zurich) in 1990. In 1986, he completed an LL.M. at McGeorge School of Law in the United States. His past memberships and positions include: the International Bar Association, where he was co-chair of the Committee on Corporate and M&A Law from 2007 to 2008; Association Internationale des Jeunes Avocats, where he was president from 1998 to 1999; and the Swiss Arbitration Association, the Zurich Bar Association, and the Swiss Bar Association.
Juergen Brokatzky-Geiger	Dr. Juergen Brokatzky-Geiger, Ph.D., has been Head Human Resources and Member of the Executive Committee at Novartis AG since January 1, 2005. Prior to that he served as Director of Human Resources at the Company from September 1, 2003. He joined Ciba-Geigy Ltd in 1983 as a Laboratory Head in the Pharmaceuticals Division. After a job rotation in the United States, he held positions of increasing responsibility in Research and Development (R&D) including Group Leader of Process R&D, Head of Process R&D, and Head of Process Development and Pilot Plant Operations. During the merger of Ciba-Geigy and Sandoz in 1996, Mr. Brokatzky-Geiger was appointed Integration Officer of Technical Operations. He later became the Head of Chemical and Analytical Development and served as the Global Head of Technical R&D from 1999 to August 2003. He graduated with a Doctorate in Philosophy (Ph.D.) in chemistry from Albert-Ludwigs-Universitaet Freiburg (the University of Freiburg), Germany, in 1982.
Kevin Buehler	Mr. Kevin J. Buehler has been Member of the Executive Committee and Division Head, Alcon at Novartis AG since April 2011. Mr. Buehler was President and Chief Executive Officer of Alcon Inc. from 2009 to 2011. He began his career with Alcon in 1984 as a Regional Sales Manager in the Consumer Products Division, and held positions of increasing responsibility before being named Director of Sales and Marketing. In 1996, he became Director of Alcon’s United States (US) Managed Care and Falcon Generic Pharmaceutical groups, and became Vice President in 1998. The following year he returned to the US Consumer Products Division as Vice President and General Manager. Mr. Buehler moved to the International Division in 2002 as Vice President and Regional Manager, Latin America and Caribbean. He was later named Area Vice President, Latin America, Canada, Australia and Far East. Mr. Buehler also served as Senior Vice President, global markets, and Chief Marketing Officer. Prior to joining Alcon, he worked for The Gillette Co. and Snyder Drug Stores. Mr. Buehler holds a Bachelor of Science degree from Carroll University in Waukesha, Wis., in the United States, with concentrations in business administration and political science. He completed the Harvard Program for Management Development in 1993.
David Epstein	Mr. David R. Epstein has been Member of the Executive Committee and Division Head, Pharmaceuticals at Novartis AG since February 1, 2010. Prior to his current position, Mr. Epstein served as Head of Novartis Oncology since 2000. He led the Molecular Diagnostics unit of the Company since 2008. He is a permanent attendee of the Executive Committee of Novartis. Before joining Novartis, Mr. Epstein was an associate in the Strategy Practice of the consulting firm, Booz Allen & Hamilton. Mr. Epstein joined Sandoz, a predecessor company of Novartis, in 1989, and held various leadership positions of increasing responsibility for the company, including Chief Operating Officer of Novartis Pharmaceuticals Corporation in the United States and Head of Novartis Specialty Medicines. Mr. Epstein graduated with a bachelors degree in pharmacy from Rutgers University College of Pharmacy in 1984, and with a Master of Business Administration in finance and marketing from New York’s Columbia University Graduate School of Business in 1987.
Mark Fishman	Dr. Mark C. Fishman, M.D., has served as Member of the Executive Committee and President of Novartis Institute for BioMedical Research (NIBR) at Novartis AG since 2002. Before joining Novartis in 2002, Dr. Fishman was Chief of Cardiology and Director of the Cardiovascular Research Center at Massachusetts General Hospital, and Professor of Medicine at Harvard Medical School, both in the United States. Dr. Fishman has worked with national policy and scientific committees, including those of the United States National Institutes of Health (NIH) and the Wellcome Trust. He completed his internal medicine residency, chief residency and cardiology training at Massachusetts General Hospital. Dr. Fishman graduated with a bachelors degree from Yale College in 1972 and a Doctorate of Medicine (M.D.) from Harvard Medical School in 1976. He has been honored with awards and distinguished lectureships, and is Member of the Institute of Medicine of the National Academies (the United States) and a Fellow of the American Academy of Arts and Sciences.
Jeff George	Mr. Jeffrey (Jeff) George has been Member of the Executive Committee and Division Head, Sandoz at Novartis AG since 2010. He has been Division Head, Sandoz since 2008. Before joining Novartis, Mr. George was a Senior Director of Strategy and Business Development at Gap Inc. From 2001 to 2004, he was with McKinsey & Company in San Francisco, United States, where he was an Engagement Manager. Mr. George joined Novartis in the Vaccines and Diagnostics Division in January 2007 as Head of Commercial Operations for Western and Eastern Europe, then advanced to Head of Emerging Markets for the Middle East, Africa, Southeast Asia and CIS at Novartis Pharma. Mr. George graduated in 1999 with a Master’s degree from the Johns Hopkins University School of Advanced International Studies, where he studied international economics and emerging markets political economy. He received a Master of Business Administration from Harvard University in 2001.
George Gunn	Mr. George Gunn has served as Member of the Executive Committee, Division Head, Novartis Animal Health; and Head of Corporate Responsibility at Novartis AG since March 2011. Prior to that, he acted as Division Head Consumer Health and Member of the Executive Committee at the Copmany since December 2008. Before joining Novartis AG, Mr. Gunn was President of Pharmacia Animal Health, based in the United States. Previously, he spent more than 15 years in positions of increasing responsibility in healthcare companies. He worked as a veterinary surgeon for nine years before joining the industry. Mr. Gunn joined Novartis in 2003 as Head of Novartis Animal Health, North America. In January 2004, he assumed his position as Head of the Animal Health Business Unit. In addition to this role, he was appointed Head of the Consumer Health Division in December 2008. Mr. Gunn graduated with a bachelor of veterinary medicine and surgery degree from the Royal (Dick) School of Veterinary Studies in the United Kingdom, in 1973. He graduated with a diploma in veterinary state medicine from the same school in 1978. In 2008, he received an honorary doctorate in veterinary medicine and surgery from the University of Edinburgh. He is Member of the Royal College of Veterinary Surgeons (MRCVS).
Andrin Oswald	Dr. Andrin Oswald, M.D., has been Member of the Executive Committee and Division Head of Vaccines and Diagnostics at Novartis AG since 2008. He is Permanent Attendee of the Executive Committee of Novartis AG. Before joining Novartis, Dr. Oswald was Delegate of the International Committee of the Red Cross to Nepal from 2002 to 2003 and worked with McKinsey & Company, Switzerland. In 2005, Dr. Oswald joined Novartis and advanced from Assistant to the Chairman and Chief Executive Officer (CEO), to Head of the Country Pharma Organization (CPO) and Country President for Novartis in South Korea, to CEO of Speedel and Global Head of Development Franchises at Novartis Pharma in 2008. Dr. Oswald graduated with a Doctorate in Medicine (M.D.) from the University of Geneva, Switzerland, in 1999.
Dimitri Azar	Dr. Dimitri Azar, M.D., has served as Member of the Board of Directors of Novartis AG since February 2012. He qualifies as an independent Non-Executive Director. He is Dean of the College of Medicine and professor of ophthalmology, bioengineering and pharmacology at the University of Illinois at Chicago in the United States, where he formerly was Head of the Department of Ophthalmology and Visual Sciences. He sits on the Board of Trustees of the Chicago Ophthalmological Society and the Association of Research in Vision and Ophthalmology. Dr. Azar is Member of the American Ophthalmological Society and holds committee positions with the American Academy of Ophthalmology. Dr. Azar began his career at the American University Medical Center, Beirut, Lebanon, and completed his fellowship and residency training at the Massachusetts Eye and Ear Infirmary at Harvard Medical School in the United States. Dr. Azar practiced at the Wilmer Ophthalmologic Institute at The Johns Hopkins Hospital School of Medicine, then returned to the Massachusetts Eye and Ear Infirmary as director of the cornea and external disease. He became professor of ophthalmology with tenure at Harvard Medical School in 2003. Dr. Azar holds an Executive Master of Business Administration from the University of Chicago, Booth School of Business.
William Brody	Dr. William R. Brody, M.D., Ph.D., has been Member of the Board of Directors at Novartis AG since February 2009. He qualifies as an Independent Non-Executive Director. He is also Member of the Compensation Committee of the Company. Dr. Brody was President of the Johns Hopkins University until the end of 2008 and is President of the United States-based Salk Institute for Biological Studies, La Jolla, California, United States. Previously he held various academic positions, including Professor for Radiology and Electrical Engineering at Stanford University and Professor and Director of the Department of Radiology at the Johns Hopkins University, both in the United States. Dr. Brody is President of the Salk Institute for Biological Studies. He is also Member of the Boards of Directors of the United States-based International Business Machines Corp. and Kool Smiles Inc., and the mutual funds boards of T. Rowe Price. He is Member of numerous professional associations, and also serves on the advisory boards of various government and nonprofit organizations. Dr. Brody earned his bachelors and masters degrees in electrical engineering from the Massachusetts Institute of Technology before completing his M.D. and Ph.D. at Stanford University, all in the United States.
Srikant Datar	Dr. Srikant Datar, Ph.D., has been Member of the Board of Directors of Novartis AG since 2003. He qualifies as Independent Non-Executive Director. He is Chairman of the Audit and Compliance Committee and Member of the Risk Committee and the Compensation Committee at the Company. Dr. Datar has worked as an accountant and planner in industry, and as a professor at Carnegie Mellon University, Stanford University and Harvard University in the United States. His research interests are in the areas of cost management, measurement of productivity, product development, timebased competition, incentives and performance evaluation. He is the author of a number of scientific publications and has received several academic awards and honors. Dr. Datar has advised and worked with numerous companies in research, development and training. Dr. Datar is Arthur Lowes Dickinson Professor at the Graduate School of Business Administration at Harvard University. He is also Member of the Board of Directors of ICF International Inc. and of Stryker Corp., both in the United States, and of KPIT Cummins Infosystems Ltd., India. He graduated with distinction in mathematics and economics from the University of Bombay, India, in 1973. He is a Chartered Accountant and holds two masters degrees and a Doctor of Philosophy (Ph.D.) from Stanford University, United States.
Ann Fudge	Ms. Ann M. Fudge has been Member of the Board of Directors at Novartis AG since February 26, 2008. She qualifies as an Independent Non-Executive Director. She is Member of the Risk Committee as well as Corporate Governance and Nomination Committee of the Company. She is former Chairwoman and Chief Executive Officer of Young & Rubicam Brands. Before that, she served as President of the Beverages, Desserts and Post Division of Kraft Foods. Ms. Fudge serves on the Board of Directors of General Electric Co., on the Board of Directors of Unilever, United Kingdom /Netherlands and on the Board of Directors of Infosys, India. She is a trustee of the New York-based Rockefeller Foundation and the Atlanta-based Morehouse College, and Chairman of the United States Programs Advisory Panel of the Bill & Melinda Gates Foundation. Ms. Fudge is further Member of the Harvard University Corporation Committee on Finance. She also sits on the Board of the Council on Foreign Relations. Ms. Fudge received her Bachelors degree from Simmons College and her Masters of Business Administration degree from Harvard University Graduate School of Business in the United States.
Pierre Landolt	Dr. Pierre Landolt, Ph.D., has been Member of the Board of Directors at Novartis AG since 1996. He qualifies as an Independent Non-Executive Director. He is Member of the Corporate Governance and Nomination Committee at the Company. From 1974 to 1976, he worked for Sandoz Brazil SA. In 1977, he acquired an agricultural estate in the semi-arid Northeast Region of Brazil and, over several years, converted it into a model farm in organic and biodynamic production. Since 1997, Dr. Landolt has been Associate and Chairman of AxialPar Ltda, Brazil, an investment company focused on sustainable development, with investments in fish farming, soybean for human consumption and organic vegetable. In 2000, he co-founded EcoCarbone SA, France, a company active in the design and development of carbon-sequestration processes in Asia, Africa, South America and Europe. In 2007, he co-founded Amazentis SA, Switzerland, a startup company active in the convergence space of medication and nutrition. He is a Member of the Board of Directors of Syngenta AG and a Partner with unlimited liabilities of the Swiss private bank Landolt & Cie. In Brazil, Dr. Landolt serves as President of the Instituto Fazenda Tamandua, the Instituto Estrela de Fomento ao Microcredito, AxialPar Ltda. and Moco Agropecuaria Ltda. In Switzerland, he is Chairman of Emasan AG and Vaucher Manufacture Fleurier SA, Vice Chairman of Parmigiani Fleurier SA, and is on the Board of the Syngenta Foundation for Sustainable Agriculture. He is Member of the Board of EcoCarbone SA, France, and Swiss Amazentis SA. He is also Vice Chairman of the Montreux Jazz Festival Foundation. Dr. Landolt graduated with a Bachelors degree in Law from the University of Paris-Assas.
Enrico Vanni	Dr. Enrico Vanni, Ph.D., has been Member of the Board of Directors at Novartis AG since 2011. He qualifies as an Independent Non-Executive Director. He is Member of the Audit and Compliance Committee, and Chairman of the Compensation Committee at the Company. He began his career as a research engineer at International Business Machines Corp. in California, and joined McKinsey & Company in Zurich, Switzerland, in 1980. He managed the Geneva office for McKinsey from 1988 to 2004, and consulted for companies in the pharmaceutical, consumer and finance sectors. He led its European pharmaceutical practice and served as Member of the Partner review committee of the firm prior to his retirement in 2007. Since his retirement as Director of McKinsey & Company in 2007, Dr. Vanni has been an independent consultant. He is currently Member of several Boards of Directors in industries from healthcare to private banking, for nonlisted companies including Eclosion2, Denzler & Partners SA and Banque Privee BCP (Suisse) SA. Dr. Vanni holds an engineering degree in chemistry from Ecole polytechnique federale de Lausanne (the Federal Polytechnic School of Lausanne), Switzerland, a Ph.D. in chemistry from Universite de Lausanne, as well as a Master of Business Administration from INSEAD in Fontainebleau, France.
Andreas von Planta	Dr. Andreas von Planta, Ph.D., has been Member of the Board of Directors at Novartis AG since February 28, 2006. He qualifies as an independent Non-Executive Director of the Company. He is Chairman of the Risk Committee, Member of the Audit and Compliance Committee, and the Corporate Governance and Nomination Committee at the Company. He passed his bar examinations in Basel in 1982. Since 1983, he has been working for the law firm Lenz & Staehelin in Geneva, where he became a partner in 1988. His areas of specialization include corporate law, corporate finance, company reorganizations, and mergers and acquisitions. Mr. von Planta is Chairman of the Schweizerische National-Versicherungs-Gesellschaft AG and a Board Member of Holcim Ltd., both in Switzerland. He is also a Board Member of various Swiss subsidiaries of foreign companies and other nonlisted Swiss companies. He is Member of the Board of Editors of the Swiss Review of Business Law and former Chairman of the Geneva Association of Business Law. Mr. von Planta is Chairman of the regulatory board of the SIX Swiss Exchange AG. Mr. von Planta holds Lizentiat des Rechts (lic. iur., LLB) and Doctorote in Philosophy (Ph.D.) degrees from Universitaet Basel, Switzerland, and an Master of Laws (LL.M.) from Columbia University School of Law, New York, United States.
Wendelin Wiedeking	Dr. Wendelin Wiedeking has been Member of the Board of Directors at Novartis AG since 2003. He qualifies as an independent Non-Executive Director. He is Member of the Audit and Compliance Committee and the Risk Committee of the Company. Dr. Wiedeking was Chairman of the Executive Board of Porsche Automobil Holding SE and of Dr. Ing. h.c. F. Porsche AG, both in Germany until July 2009. Since then he has been an entrepreneur. His professional career began in 1983 in Germany as Director’s Assistant in the Production and Materials Management area of Dr. Ing. h.c. F. Porsche AG in Stuttgart-Zuffenhausen. In 1988, he moved to Glyco Metall-Werke KG in Wiesbaden as Division Manager, where he advanced by 1990 to the position of Chief Executive Officer and Chairman of the Board of Management of Glyco AG. In 1991, he returned to Dr. Ing. h.c. F. Porsche AG as Production Director. A year later, the Supervisory Board appointed him Spokesman of the Executive Board (CEO), and Chairman in 1993. Dr. Wiedeking graduated in mechanical engineering in 1978 and worked as a scientific assistant in the Machine Tool Laboratory of the Rhine-Westphalian College of Advanced Technology in Germany.
Mun Tak Yang	Ms. Marjorie Mun Tak Yang has been Member of the Board of Directors at Novartis AG since January 1, 2008. She qualifies as an Independent Non-Executive Director of the Company. She is also Member of the Compensation Committee of the Company. From 1976 to 1978, she was an associate in Corporate Finance, Mergers and Acquisitions with the First Boston Corporation in New York, United States. In 1979, she returned to Hong Kong and became a founding member of Esquel Group. She was appointed Chairwoman of the Group in 1995. Ms. Yang is Chairman of the Esquel Group, Hong Kong, China. She is Member of the Executive Council of the Hong Kong Special Administrative Region. In China, she is Member of the National Committee of the Chinese People’s Political Consultative Conference. She currently serves on the boards of Swire Pacific Limited, and The Hong Kong and Shanghai Banking Corporation Limited in Hong Kong. Ms. Yang has been Member of the MIT Corporation since 2001. In January 2010 she was appointed Chairwoman of the Council of the Hong Kong Polytechnic University. She also serves on the Advisory Boards of Harvard Business School and Tsinghua School of Economics and Management. From 2001 to 2011, Ms. Yang was Member of the MIT Corp. Ms. Yang graduated with a Bachelors degree in Mathematics from Massachusetts Institute of Technology and holds a Masters degree from Harvard Business School, both in the United States.
Rolf Zinkernagel	Dr. Rolf M. Zinkernagel, M.D., has been Member of the Board of Directors at Novartis AG since May 1999. He qualifies as an Independent Non-Executive Director. He is Member of the Corporate Governance and Nomination Committee of the Company. Dr. Zinkernagel was Vice President of the International Union of Immunological Societies until 2010. He is Member of the scientific advisory boards of Bio-Alliance AG, Germany; Aravis General Partner Ltd., Cayman Islands and Switzerland; Telormedix, Switzerland; X-Biotech, Canada; Novimmune, Switzerland; Cancevir, Switzerland; Nuvo Research Inc., Canada; ImVision, Germany; MannKind, United States; and Biomedical Sciences International Advisory Council, Singapore. Dr. Zinkernagel is also a science consultant to Chilka Ltd., Cayman Islands; Ganymed, Germany; and Zhen-Ao Group, China. He is Member of the scientific advisory panel of Swiss Re, Switzerland. Dr. Zinkernagel graduated from Universitaet Basel, Switzerland, with a Doctor of Medicine (M.D.) in 1970. From 1992 to 2008, he was a professor and director of the Institute of Experimental Immunology at the University of Zurich and after his retirement in 2008, continues to be active at the University of Zurich. Dr. Zinkernagel has received awards and prizes for his work and contribution to science, notably the Nobel Prize in medicine, which he was awarded in 1996.

Basic Compensation

Name	Fiscal Year Total
Daniel Vasella	13,067,600
Joseph Jimenez	13,228,200
Ulrich Lehner	853,107
Jon Symonds	4,646,210
Felix Ehrat	3,584,790
Juergen Brokatzky-Geiger	3,474,440
Kevin Buehler	6,882,100
David Epstein	7,562,660
Mark Fishman	7,848,220
Jeff George	2,915,310
George Gunn	4,094,650
Andrin Oswald	2,496,680
Dimitri Azar	350,025
William Brody	525,045
Srikant Datar	720,051
Ann Fudge	450,038
Pierre Landolt	424,027
Enrico Vanni	540,161
Andreas von Planta	589,074
Wendelin Wiedeking	529,656
Mun Tak Yang	424,229
Rolf Zinkernagel	684,420

As Of 30 Dec 2012

Options Compensation

Name	Options	Value
Daniel Vasella	0	0
Joseph Jimenez	0	0
Ulrich Lehner	0	0
Jon Symonds	0	0
Felix Ehrat	0	0
Juergen Brokatzky-Geiger	0	0
Kevin Buehler	0	0
David Epstein	0	0
Mark Fishman	0	0
Jeff George	0	0
George Gunn	0	0
Andrin Oswald	0	0
Dimitri Azar	0	0
William Brody	0	0
Srikant Datar	0	0
Ann Fudge	0	0
Pierre Landolt	0	0
Enrico Vanni	0	0
Andreas von Planta	0	0
Wendelin Wiedeking	0	0
Mun Tak Yang	0	0
Rolf Zinkernagel	0	0

Insider Trading

» Full list on Insider Trading

People: Novartis AG (NVS)

Related Topics:

Summary

Biographies

Basic Compensation

Options Compensation

Related Topics: